EDESA BIOTECH INC

CEO’s $5.21 private purchase of 153,550 EDESA shares signals growing insider confidence in the biotech’s pipeline and could buoy the stock amid high volatility.

CEO Pardeep Nijhawan’s fresh buy of 1,159 Edesa Biotech shares signals deep insider confidence in its dermatology pipeline and upcoming milestones.

CEO’s fresh insider buy of Edesa Biotech shares shows confidence in upcoming clinical milestones, hinting at a potential upside for long‑term investors.

CEO Pardeep Nijhawan’s steady buying at low prices shows Edesa Biotech’s strong outlook—boosted by 516% monthly earnings, 58% weekly gains and a disciplined 10k‑share strategy. Investors may spot upside before the stock hits new highs.

CEO’s recent 10,000‑share buy at $3.26 signals confidence for Edesa Biotech, yet investors must weigh weak earnings, clinical milestones, and potential dilution.

Insider buying boosts optimism for Edesa Biotech—CEO’s latest 10k-share purchase signals confidence ahead of key clinical milestones.

CEO Nijhawan Pardeep’s recent bulk buy of Edesa Biotech shares at $2 each signals bullish confidence amid a 337% rally, suggesting optimism for upcoming clinical milestones.

CEO Nijhawan Pardeep’s recent bulk buying of Edesa Biotech shares signals insider confidence, hinting at potential upside as the company advances its clinical pipeline.